share_log

Pfizer | DEFA14A: Others

Pfizer | DEFA14A: Others

輝瑞 | DEFA14A:其他
美股sec公告 ·  04/11 11:04
Moomoo AI 已提取核心訊息
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.
根據美國證券交易委員會最近的一份文件,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的額外材料,這是其委託聲明附表14A的一部分。根據1934年《證券交易法》第14(a)條,該文件不是初步的,不收取任何費用,是上市公司的標準程序。這些材料是爲輝瑞的股東準備的,不構成招標材料。這一舉措表明,輝瑞正在爲即將到來的與股東的交易做準備,儘管公告中沒有披露這些材料的具體內容。
根據美國證券交易委員會最近的一份文件,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的額外材料,這是其委託聲明附表14A的一部分。根據1934年《證券交易法》第14(a)條,該文件不是初步的,不收取任何費用,是上市公司的標準程序。這些材料是爲輝瑞的股東準備的,不構成招標材料。這一舉措表明,輝瑞正在爲即將到來的與股東的交易做準備,儘管公告中沒有披露這些材料的具體內容。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息